Oncology Today with Dr Neil Love

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00) Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10...

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00) A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11) Current and future role of avutometinib with defactinib for LGSOC (19:23) A Phase II/III trial of tr...

Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09) Potential mechanisms of adverse events documented with TKI...

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and ha...

Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics: Introduction (0:00) Best Option for Your Patient (1:28) Biological Considerations (6:26) KRAS G12C Inhibitors (11:33) Second-Line Treatment (13:02) Current Clinical Trials in the First-Line Metastatic Setting (32:18) Current Clinical Trials in the Localized Setting (49:52) Current Clinical Trial...

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics: Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00) Nonmetastatic Disease (10:32) Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50) CME information and select publications

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00) Case: A man in hi...

Featuring perspectives from Prof John Seymour, including the following topics: Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00) Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21) First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10) CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metasta...

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics: Introduction (0:00) HER2 History (1:32) Cases from the GMO Survey (7:06) Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56) Faculty Case Presentations (31:37) Patterns of Care Survey — Part 1 (38:26) Optimizing the Use of Up-Fr...

Featuring perspectives from Dr William G Wierda, including the following topics: Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00) Sequencing Road Map (12:39) Key Datasets — Pirtobrutinib (21:08) Investigator Survey (34:09) Chimeric Antigen Receptor T-Cell Therapy (45:08) Other Novel Therapy Approaches (49:58) EHA 2026 (54:45) CME information and select publ...

Featuring an interview with Prof Ticiana Leal, including the following topics: Pathophysiology and clinical signs and symptoms (0:00) Screening and/or diagnostic approaches (5:45) Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36) Key clinical trial data for amifampridine and practicalities of its administration (14:05) Building awareness a...

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics: Introduction (0:00) Overview of Prostate Cancer (3:00) Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12) Potential Role of Capivasertib in Metastatic HSPC (27:22) Current and Potential Future Role...

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics: Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00) First-Line Therapy (PD-L1 Negative) (6:53) First-Line Therapy (PD-L1 Positive) (23:40) Second-Line Therapy (Sequencing) (34:08) Adverse Events with TROP2-Targeting ADCs (43:43) CME infor...

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A patient with T4 disease, pelvic wall involvement and a positive pelvic node treated as metastatic disease with enfortumab vedotin and pembrolizumab attains a complete response on imaging after 6 cycles (0:00) Case: A man...

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A man in his early 80s with non-muscle-invasive bladder cancer (NMIBC) monitored by repeat TURBTs develops localized muscle-invasive bladder cancer and enrolls in a clinical trial of neoadjuvant enfortumab vedotin with pem...

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics: Introduction: Lymphoma Survivorship (0:00) Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49) Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14) CME information and select publications

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics: Introduction (0:00) Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29) Recent Advances in Up-Front Treatment for Metastatic PAD (15:47) Selection and Sequencing of Therapy for Relapsed/Refractory Metas...

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction: San Antonio Memories (0:00) PI3K/AKT/PTEN Alterations and Therapies (7:18) Capivasertib (20:22) Gedatolisib (34:08) Inavolisib (47:07) New Agents and Ongoing Trials (52:34) CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation se...

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that pr...

Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics: Introduction (00:00) Biomarker Evaluation in Localized and Metastatic Disease (1:49) Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37) Other Available Therapeutic Approaches — Dr Shitara (33:22) CME information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics: Introduction: Welcome GU Oncology Fellows! (0:00) Prostate Cancer — Dr Aggarwal (12:48) Urothelial Bladder Cancer — Dr Galsky (45:01) Renal Cell Carcinoma — Dr Zhang (1:10:52) CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics: Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00) Case: A man in his early 70s with diabetes who received adjuvant...

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics: Introduction (0:00) Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37) Practical Considerations with Oral SERDs (15:42) Potential Role of Combination Approa...